JP2016522830A5 - - Google Patents

Download PDF

Info

Publication number
JP2016522830A5
JP2016522830A5 JP2016514532A JP2016514532A JP2016522830A5 JP 2016522830 A5 JP2016522830 A5 JP 2016522830A5 JP 2016514532 A JP2016514532 A JP 2016514532A JP 2016514532 A JP2016514532 A JP 2016514532A JP 2016522830 A5 JP2016522830 A5 JP 2016522830A5
Authority
JP
Japan
Prior art keywords
cells
pbmc
use according
derived
degeneration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016514532A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016522830A (ja
JP6474082B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2014/050463 external-priority patent/WO2014188436A1/en
Publication of JP2016522830A publication Critical patent/JP2016522830A/ja
Publication of JP2016522830A5 publication Critical patent/JP2016522830A5/ja
Application granted granted Critical
Publication of JP6474082B2 publication Critical patent/JP6474082B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016514532A 2013-05-22 2014-05-22 眼疾患および眼障害の治療のためのヒト単球亜集団 Expired - Fee Related JP6474082B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361826159P 2013-05-22 2013-05-22
US61/826,159 2013-05-22
US201361915069P 2013-12-12 2013-12-12
US61/915,069 2013-12-12
PCT/IL2014/050463 WO2014188436A1 (en) 2013-05-22 2014-05-22 Human monocyte sub-population for treatment of eye diseases and disorders

Publications (3)

Publication Number Publication Date
JP2016522830A JP2016522830A (ja) 2016-08-04
JP2016522830A5 true JP2016522830A5 (cg-RX-API-DMAC7.html) 2017-06-29
JP6474082B2 JP6474082B2 (ja) 2019-02-27

Family

ID=51933057

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016514532A Expired - Fee Related JP6474082B2 (ja) 2013-05-22 2014-05-22 眼疾患および眼障害の治療のためのヒト単球亜集団

Country Status (11)

Country Link
US (1) US10188679B2 (cg-RX-API-DMAC7.html)
EP (1) EP2999479B1 (cg-RX-API-DMAC7.html)
JP (1) JP6474082B2 (cg-RX-API-DMAC7.html)
KR (1) KR102257163B1 (cg-RX-API-DMAC7.html)
CN (1) CN105377273A (cg-RX-API-DMAC7.html)
AU (1) AU2014269935B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015029299A2 (cg-RX-API-DMAC7.html)
CA (1) CA2913274C (cg-RX-API-DMAC7.html)
IL (1) IL242694B (cg-RX-API-DMAC7.html)
MX (1) MX2015016062A (cg-RX-API-DMAC7.html)
WO (1) WO2014188436A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013088441A1 (en) * 2011-12-14 2013-06-20 Yeda Research And Development Co. Ltd Human monocyte sub-population for treatment of central nervous system injury
US11162070B2 (en) 2015-09-08 2021-11-02 FUJIFILM Cellular Dynamics, Inc. MACS-based purification of stem cell-derived retinal pigment epithelium
DE102017125335B4 (de) * 2017-10-27 2019-10-17 Epiontis Gmbh Amplikon-Region als epigenetischer Marker zur Identifizierung von Immunzellen, insbesondere nicht-klassischer Monozyten
KR102228401B1 (ko) * 2018-07-05 2021-03-16 고려대학교 산학협력단 유리체 절제술 및 안구 내 mnu 주입과 제거를 이용한 망막 변성 동물 모델의 제조방법 및 이를 이용한 망막 변성 동물 모델
MX2022007107A (es) * 2019-12-11 2022-11-14 Myeloid Therapeutics Inc Composiciones celulares terapeuticas y metodos de preparacion y usos de las mismas.
CN116440253A (zh) * 2023-02-27 2023-07-18 中山大学中山眼科中心 修复型免疫细胞亚群的诱导方法及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267955B1 (en) 1995-09-15 2001-07-31 Yeda Research And Development Co. Ltd. Mononuclear phagocytes and their use to promote axonal regeneration
US5800812A (en) 1995-09-15 1998-09-01 Yeda Research And Development Co. Ltd. Methods of use of mononuclear phagocytes to promote axonal regeneration
AU2002353465B2 (en) 2001-11-21 2008-10-16 Yeda Research And Development Co. Ltd. Process for the manufacture of human mononuclear phagocytic leukocytes
RU2418856C2 (ru) * 2005-02-24 2011-05-20 Дзе Скриппс Рисерч Инститьют Изолированные популяции миелоидоподобных клеток костного мозга и способы лечения с ними
AU2010216374A1 (en) * 2009-02-20 2011-08-18 The Scripps Research Institute Isolated monocyte populations and related therapeutic applications
WO2013088441A1 (en) * 2011-12-14 2013-06-20 Yeda Research And Development Co. Ltd Human monocyte sub-population for treatment of central nervous system injury

Similar Documents

Publication Publication Date Title
CA3045733C (en) Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases
JP2012505162A5 (cg-RX-API-DMAC7.html)
Semba et al. Brimonidine prevents neurodegeneration in a mouse model of normal tension glaucoma
JOP20170147B1 (ar) تركيبة عينية تشتمل على زيت الخروع ودهون ثلاثية متوسطة السلسلة
MX2010003774A (es) Formulaciones oftalmicas acuosas.
WO2015138628A8 (en) Use of aav-expressed m013 protein as an anti-inflammatory therapeutic
EA201170551A1 (ru) Способы лечения заболеваний глаз
Grieb et al. Citicoline: a food beneficial for patients suffering from or threated with glaucoma
RU2014123472A (ru) Производные 4-прегенен-11ss-17-21-триол-3,20-диона для лечения глазных болезней
JP2013528563A5 (cg-RX-API-DMAC7.html)
RU2017116974A (ru) Офтальмологическая композиция, содержащая циклоспорин и трегалозу
MY203247A (en) Anti-trkb monoclonal antibodies and methods of use
RU2014125426A (ru) Защитное средство для роговицы и конъюнктивы или супрессивное средство при кератоконъюнктивальном нарушении
JP2017525758A5 (cg-RX-API-DMAC7.html)
WO2013184650A3 (en) Treatment of ocular inflammatory diseases using laquinimod
Scholl et al. The use of neuroprotective agents in treating geographic atrophy
AR079683A1 (es) Formulacion topica oftalmica de peptidos
EA202192183A1 (ru) Композиции, обладающие активностью удаления липофусцина из клеток сетчатки
BR112015029299A2 (pt) subpopulação de monócitos humanos para tratamento de doenças e distúrbios oculares
JP2015514760A5 (cg-RX-API-DMAC7.html)
CL2020001426A1 (es) Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo.
NZ622403A (en) Method for screening an agent being useful for the treatment of dry eye and/or corneal and conjunctival lesion and a pharmaceutical composition obtained by the method
Amalnath et al. Ocular signs in Wilson disease
Park et al. The analysis of peripapillary RNFL, macula and macular ganglion cell layer thickness in patients with monocular amblyopia using SD-OCT
Li et al. Analysis of the correlation between tear film changes of allergic conjunctivitis and dry eye